Takeda’s chief executive Yasuchika Hasegawa has admitted the company may have used “inappropriate” language in its marketing of blood pressure blockbuster Blopress, but denied any data falsification. Hasegawa told the Wall Street Journal that the company had used a graph in promotional literature indicating Blopress (candesartan cilexetil) was more effective than rival blood pressure drug Norvasc (amlodipine) from Pfizer which was not supported by clinical data. Blopress - also sold as Atacand - was a big seller for Takeda for many years, with sales approaching $2bn before it lost patent protection in 2012.
Help employers find you! Check out all the jobs and post your resume.
